<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01458119</url>
  </required_header>
  <id_info>
    <org_study_id>AT1001-041</org_study_id>
    <nct_id>NCT01458119</nct_id>
  </id_info>
  <brief_title>Open-Label Phase 3 Long-Term Safety Study of Migalastat</brief_title>
  <acronym>AT1001-041</acronym>
  <official_title>An Open-Label Extension Study to Evaluate the LongTerm Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amicus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amicus Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long term, open label study of migalastat HCl (AT1001) in subjects with Fabry
      disease who completed treatment in a previous monotherapy trial with migalastat hydrochloride
      (HCl).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AT1001-041 is an open-label, non-comparative, multicenter, long term extension study for
      subjects with Fabry disease who have completed treatment in a previous trial of migalastat
      HCl (also known as AT1001) given as monotherapy. This is an extension study designed to
      evaluate the long-term safety and efficacy of migalastat HCl for the treatment of Fabry
      disease. Study visits will occur every 6 months to evaluate safety and assess efficacy. Visit
      evaluations will include physical examination, clinical laboratory parameters, adverse events
      and patient reported outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>non-serious AEs, serious AEs, and possible suicidality related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Withdrawal from treatment due to AEs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>including non-serious and serious AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in vital signs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>blood pressure, heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in laboratory parameters</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>blood chemistry, hematology, urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in electrocardiogram (ECG)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in echocardiography (ECHO)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>ECHO ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>based on the Modification of Diet in Renal Disease equation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of 24-hour urine</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>protein, albumin, creatinine and globotriaosylceramide (GL-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of left ventricular mass index and ejection fraction</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>as measured by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of leukocyte alpha-galactosidase A (a-Gal A) activity</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>enzyme responsible for breaking down GL-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of patient reported assessment of pain</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>as assessed by the Brief Pain Inventory short form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of patient reported Quality of Life</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>as assessed by the Short Form-36 survey</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>migalastat HCl 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Migalastat HCl s provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken taken on the days between migalastat HCl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>migalastat HCl 150mg</intervention_name>
    <description>Provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken taken on the days between migalastat HCl.</description>
    <arm_group_label>migalastat HCl 150 mg</arm_group_label>
    <other_name>AT1001</other_name>
    <other_name>Galafold</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed migalastat HCl treatment in a previous Fabry disease protocol

          -  Both: both female and male participants are being studied

          -  Ages 16 years or older

          -  Males and females must agree to use protocol identified acceptable contraception

        Exclusion Criteria:

          -  Estimated glomerular filtration rate in the previous study was &lt;30 mL/min/1.73m2;
             unless there is measured GFR available within 3 months of Baseline Visit (Visit 1),
             which is &gt;30 mL/min/1.73m2

          -  Has undergone, or is scheduled to undergo kidney transplantation or is currently on
             dialysis

          -  Pregnancy or breast feeding

          -  Treated with another investigational drug (except migalastat HCl) within 30 days of
             study start

          -  Unable to comply with study requirements, or deemed otherwise unsuitable for study
             entry, in the opinion of the investigator

          -  Has documented transient ischemic attack, stroke, unstable angina, or myocardial
             infarction within the 12 months before Visit 1

          -  Has clinically significant unstable cardiac disease in the opinion of the investigator

          -  Has history of allergy or sensitivity to AT1001 (including excipients) or other
             iminosugars

          -  Requires treatment with Glyset, (miglitol), or Zavesca (miglustat)

          -  Has any intercurrent illness or condition that may preclude the subject from
             fulfilling the protocol requirements

          -  Patients with severe or unsuitable concomitant medical condition

          -  Patients with clinically significant abnormal laboratory value(s) and clinically
             significant electrocardiogram (ECG) findings at baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, Clinical Research</last_name>
    <role>Study Director</role>
    <affiliation>Amicus Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infusion Associates N. E.</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O &amp; O Alpan</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral</name>
      <address>
        <city>Pilar</city>
        <zip>B1629ODT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's and Children's Hospital</name>
      <address>
        <city>North Adelaide</city>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antwerpen Koningin Paola Kinderziekenhuis</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasr El Ainy Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11451</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gazi University Medical Faculty Gazi Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital</name>
      <address>
        <city>Salford</city>
        <state>Greater Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Japan</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2011</study_first_submitted>
  <study_first_submitted_qc>October 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2011</study_first_posted>
  <disposition_first_submitted>May 23, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>May 23, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 25, 2017</disposition_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry disease</keyword>
  <keyword>Lysosomal storage disease</keyword>
  <keyword>migalastat HCl</keyword>
  <keyword>AT1001</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1-Deoxynojirimycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

